Qualigen Therapeutics Inc (QLGN) — Capital Reinvestment Ratio

Latest as of September 2023: 0.27x

Qualigen Therapeutics Inc (QLGN) has a Capital Reinvestment Ratio of 0.27x as of September 2023, meaning it reinvests 0% of its operating cash flow ($929.74K) in capital expenditures ($246.42K). Check Qualigen Therapeutics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.27x

Capex / Operating Cash Flow

Operating Cash Flow

$929.74K

USD

Capital Expenditures

$246.42K

USD

Data as of

Sep 2023

Most recent filing

Qualigen Therapeutics Inc Capital Reinvestment Ratio (2019–2019)

This chart tracks Qualigen Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Qualigen Therapeutics Inc.

Annual Capital Reinvestment Ratio for Qualigen Therapeutics Inc (2019–2019)

Year-by-year Capital Reinvestment Ratio for Qualigen Therapeutics Inc from 2019 to 2019. See Qualigen Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change
2019	3.39x	$57.33K	$194.48K	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow